PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform
Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.
You may also be interested in...
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.
Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.